Glucagon-like peptide-1-(7-36)amide is transformed to glucagon-like peptide-1-(9-36)amide by dipeptidyl peptidase IV in the capillaries supplying the L cells of the porcine intestine

Endocrinology

Volumn 140, Issue 11, 1999, Pages 5356-5363

  Hansen, Lene ^a   Deacon, Carolyn F ^a   Ørskov, Cathrine ^a   Holst, Jens J ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

DIPEPTIDYL PEPTIDASE IV; GLUCAGON LIKE PEPTIDE 1; GLUCAGON LIKE PEPTIDE 1 [7-36] AMIDE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; HORMONE DETERMINATION; HORMONE RELEASE; IMMUNOHISTOCHEMISTRY; INTESTINE; INTESTINE BLOOD FLOW; L CELL; NONHUMAN; PRIORITY JOURNAL; SWINE;

EID: 0033303516     PISSN: 00137227     EISSN: None     Source Type: Journal    
DOI: 10.1210/endo.140.11.7143     Document Type: Article

References (43)

1. Glucagon-like peptide-1, a new hormone of the entero-insular axis
2. Enteroglucagon
3. Complete sequences of glucagon-like peptide-1 from human and pig small intestine
4. Both amidated and nonamidated forms of glucagon-like peptide-1 are synthesized in the rat intestine and pancreas
5. Truncated glucagon-like peptide-1, an insulin-releasing hormone from the distal gut
6. Insulinotropin: Glucagon-like peptide-I (7-37) co-encoded in the glucagon gene is a potent stimulator of insulin release in the perfused rat pancreas
7. Human colon produces fully processed glucagon-like peptide-1 (7-36) amide
8. Degradation of glucagon-like peptide-1 by human plasma in vitro yields an N-terminally truncated peptide that is a major endogenous metabolite in vivo
9. 2-terminus in type II diabetic patients and in healthy subjects
10. Glucagon-like peptide-1 (9-36)amide is a major metabolite of glucagon-like peptide-1 (7-36)amide after in vivo administration to dogs, and acts as an antagonist on the pancreatic receptor
11. Glucagon-like peptide 1 undergoes differential tissue-specific metabolism in the anesthetized pig
12. Dipeptidyl peptidase IV hydrolyses gastric inhibitory polypeptide, glucagon-like peptide-1 (7-36)amide, peptide histidine methionine and is responsible for their degradation in human serum
13. Degradation of glucose-dependent insulinotropic polypeptide (GIP) and truncated glucagon-like peptide 1 (tGLP-1) in vitro and in vivo by dipeptidyl peptidase IV
14. Glucagon-like peptide-1 (7-36)amide's inhibitory effect on antral motility is antagonised by its N-terminally truncated metabolite, glucagon-like peptide 1 (9-36)amide
15. The intestinal mucosa preferentially releases somatostatin-28 in pigs
16. Secretin release from the isolated, vascularly perfused pig duodenum
17. Glucagon-like peptides GLP-1 and GLP-2, predicted products of the glucagon gene, are secreted separately from pig small intestine but not pancreas
18. Assays for peptide products of somatostatin gene expression
19. Pancreatic and intestinal processing of proglucagon in man
20. Demonstration of proteases in basal cell carcinomas. A histochemical study using amino acid-4-methoxy-2-naphthylamides as chromogenic substrates
21. Potential therapeutic levels of glucagon-like peptide I achieved in humans by a buccal tablet
22. Tissue and plasma concentrations of amidated and glycine-extended glucagon-like peptide-1 in humans
23. Proglucagon products in the plasma of non-insulin dependent diabetics and nondiabetic controls in the fasting state and following oral glucose and intravenous arginine
24. Comparison of dipeptidyl peptidase IV prepared from pig liver and kidney
25. Investigation of glucose-dependent insulinotropic polypeptide-(1-42) and glucagon-like peptide-1-(7-36) degradation in vitro by dipeptidyl peptidase IV using matrix-assisted laser desorption/ionization-time of flight mass spectrometry. A novel kinetic approach
26. A novel form of dipeptidyl peptidase IV found in human serum. Isolation, characterisation and comparison with T lymphocyte membrane dipeptidyl peptidase IV (CD26)
27. Dipeptidyl peptidase IV inhibition potentiates the insulinotropic effect of glucagon-like peptide-1 in the anesthetized pig
28. Improved glucose tolerance in Zucker fatty rats by oral administration of the dipeptidyl peptidase IV inhibitor isoleucine thiazolidide
29. Improved glucose tolerance in rats treated with the dipeptidyl peptidase IV (CD26) inhibitor ile-thiazolidide
30. Verfahren zur Herstellung neuer Inhibitoren der Dipeptidyl Peptidase IV
31. Are diprotin A (Ile-Pro-Ile) and diprotin B (Val-Pro-Leu) inhibitors or substrates of dipeptidyl peptidase IV?
32. Dipeptidyl peptidase IV is sorted to the secretory granules in pancreatic islet A-cells
33. Regulation of the biological activity of glucagon-like peptide 2 in vivo by dipeptidyl peptidase IV
34. Circulating and tissue forms of the intestinal growth factor, glucagon-like peptide-2
35. Vagal hepatopancreatic reflex effect evoked by intraportal appearance of tGLP-1
36. Intraportal GLP-1 administration augments the insulin response to portal glucose via non-muscarinic nerves
37. The inhibitory effect of glucagon-like peptide-1 (GLP-1) 7-36 amide on gastric acid secretion in humans depends on an intact vagal innervation
38. Mechanisms of the anti-diabetogenic action of subcutaneous glucagon-like peptide-1 (7-36)amide in non-insulin dependent diabetes mellitus
39. Glucagon-like peptide-1 inhibits gastropancreatic function by inhibiting central parasympathetic outflow
40. Glucagon-like peptide-1 inhibits gastric emptying via vagal afferent-mediated central mechanisms
41. The release of gastric inhibitory peptide, glucagon-like peptide-I, and insulin after oral glucose test in colectomized subjects
42. GLP-1 release in man after lower large bowel resection or intra rectal glucose administration
43. The influence of the colon on post prandial glucagon-like peptide-1 (7-36)amide concentrations in man